An Indian manufacturer of generic prescription drugs can accomplish what American counterparts cannot. Here's why.
News & Analysis: Dr. Reddy's Laboratories
A settlement in a closely watched Ohio case averted a federal trial and paves the way to a nationwide settlement -- if drug companies shorten their payment timelines.
The company's shares fall hard in the wake of reporting disappointing results.
These value stocks may be down, but they're far from out.
Trading was quiet in the post-Thanksgiving session, but these stocks dropped. Find out why.
Dr. Reddy’s Labs, Jazz, and Sanofi could all make health care headlines this morning. Here’s why.
Dr. Reddy's Laboratories, Teva Pharmaceuticals, and others gain FDA approval for generic versions of Eli Lilly's Cymbalta.
Since 1983, Depakote ER has been a good source of revenue for drug manufacturers. But is its future as sunny?
Treatment for epilepsy and bipolar disorder had over $300 million in sales in the last 12 months.
Just the facts, Fool.